Table 2.
Comparison of baseline characteristic between train set and test set
| Parameters | Train (n = 141) | Test (n = 61) | p value |
|---|---|---|---|
| Age (years) | 28.000 [23.000, 33.000] | 27.000 [21.000, 31.000] | 0.116 |
| Sex (F/M) | 61/80 | 25/36 | 0.764 |
| Wall thickening (mm) | 5.000 [3.000, 7.000] | 4.000 [3.000, 6.000] | 0.299 |
| Segmental mural hyperenhancement (Stratified/Homogeneous) | 114/27 | 48/13 | 0.723 |
| Strictures (Yes/No) | 32/109 | 12/49 | 0.204 |
| with upstream dilation (Yes/No) | 8/133 | 7/54 | 0.149 |
| Fibrofatty proliferation | 38/103 | 20/41 | 0.400 |
| Engorged vasa recta (Yes/No) | 30/101 | 17/44 | 0.309 |
| inflammation (Yes/No) | 22/119 | 7/54 | 0.442 |
| Regional Lymph node (diameter ≥ 0.5) (Yes/No) | 57/84 | 19/42 | 0.211 |
| Arterial Phase | |||
| Zeff | 8.200 [7.780, 8.470] | 8.220 [7.860, 8.410] | 0.895 |
| IC (mg/mL) | 1.580 [0.850, 2.190] | 1.670 [0.930, 2.070] | 0.759 |
| NIC | 0.129 [0.079, 0.180] | 0.143 [0.074, 0.197] | 0.706 |
| λ HU | 1.880 [1.070, 2.618] | 2.060 [1.088, 2.563] | 0.802 |
| Venous Phase | |||
| Zeff | 8.240 [8.000, 8.380] | 8.150 [7.890, 8.360] | 0.194 |
| IC (mg/mL) | 1.710 [1.170, 2.010] | 1.480 [1.060, 1.970] | 0.257 |
| NIC | 0.366 ± 0.106 | 0.335 ± 0.119 | 0.092 |
| λ HU | 2.120 [1.465, 2.495] | 1.850 [1.323, 2.452] | 0.269 |
Zeff Z-effective, λ HU slope of the energy spectrum curve, IC iodine concentration, NIC normalised iodine concentration